Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025
Can-Fite BioPharma shares surged over 30% Tuesday after reporting a patient with advanced hepatocellular carcinoma remained cancer-free for nine years on its drug Namodenoson. The company also began enrolling patients in a pivotal Phase III trial for the treatment in Israel, Europe, and the U.S. Namodenoson holds Orphan Drug and Fast Track designations.
